← All trials
NCT07060508
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2025
- Primary completion
- Feb 28, 2026
- Completion date
- Feb 28, 2026
- First posted
- Jul 11, 2025
- Last posted
- Aug 28, 2025
- Enrollment
- 290
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Indiana UniversityCollaborator
- University of WashingtonCollaborator
- Harvard UniversityCollaborator
- National Institutes of Health (NIH)Collaborator
- National Institutes of Health (NIH)Official
- Malaria Research and Training Center, Bamako, MaliCollaborator
- University of the Sciences, Techniques and Technologies of BamakoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.